



**COMPANY ANNOUNCEMENT**  
**30 July 2009**

**RESIGNATION OF DIRECTOR**

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience services provider and drug development company, today announces the resignation of Mr John Hannaford from the board of the Company.

Mr Hannaford, a non-executive director, is standing down from the board as part of the Company's restructuring and focus on cost minimisation. The Board would like to acknowledge Mr Hannaford's commitment to the Company as a founding director and thank him for his efforts and contributions over the past 4 years.

Please find attached Appendix 3Z for Mr John Hannaford.

**-ENDS-**

**CONTACTS**

Company	
David McAuliffe Executive Director	Chris Moyes Chief Executive Officer
T: +61 (0)408 994 313	T: +44 (0)7802 586 573 (after 4pm AEST for UK time zone)
E: <a href="mailto:macdavid@iinet.net.au">macdavid@iinet.net.au</a>	E: <a href="mailto:CMoyes@neurosolutionsltd.com">CMoyes@neurosolutionsltd.com</a>

**About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed speciality neuroscience services provider and drug development company which owns 100% of NeuroSolutions Ltd (ASX Code NDL).

**About NeuroSolutions**

NeuroSolutions Limited is a profitable service company, which has applied its broad spectrum expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.

During 2008, the Company reported success in a Phase II trial for NSL-101. The Company also successfully completed two Phase I trials for the development compound NSL-043, in partnership with Sosei Co. Ltd. Both of these trials reported a successful outcome.

*Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>NeuroDiscovery Ltd</b>
<b>ABN</b>	<b>89 113 824 141</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Mr John Hannaford
<b>Date of last notice</b>	1 August 2007
<b>Date that director ceased to be director</b>	30 July 2009

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
21,765 Ordinary Shares.

---

+ See chapter 19 for defined terms.

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest</small>	<b>Number &amp; class of securities</b>
<b>Riverview Corporation Pty Ltd – Mr. Hannaford</b> is a director and shareholder. Relevant interest arises under Section 608(3) of the Corporations Act.	133,521 Ordinary Shares 150,000 Unlisted options exercisable at \$0.20 expiring on or before 30 November 2009
<b>Emma Hannaford</b> - spouse	21,765 Ordinary Shares
<b>John Hannaford &lt;Amy Hannaford A/C&gt;</b>	21,765 Ordinary Shares

**Part 3 – Director's interests in contracts**

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.